Morgan Stanley has signed a Global Replication Licence with ERI Scientific Beta for in-depth risk and performance evaluation on all of Scientific Beta indices as well as the possibility to develop indices utilising the entire Scientific Beta offering on the dedicated platform. With this Global Replication Licence, Morgan Stanley is entitled to replicate Scientific Beta indices and will have the capacity to share information with all the counterparties of a fund or mandate relating to the replication of a Scientific Beta index.
ERI Scientific Beta is pleased to announce that Morgan Stanley has signed a Global Replication Licence with ERI Scientific Beta for in-depth risk and performance evaluation on all of Scientific Beta indices as well as the possibility to develop indices utilising the entire Scientific Beta offering on the www.scientificbeta.com platform.
With this Global Replication Licence, Morgan Stanley is entitled to replicate Scientific Beta indices and will have the capacity to share information with all the counterparties of a fund or mandate relating to the replication of a Scientific Beta index. Besides, the ERI Scientific Beta platform will enable Morgan Stanley to access the most extensive offering of smart beta indices and the selection and tracking/evaluation tools for these indices with full transparency and without any additional cost relating to the use of Scientific Beta data.
Hitendra Varsani, Head of Quantitative and Derivative Strategies at Morgan Stanley said, “Morgan Stanley is excited to partner with ERI Scientific Beta in delivering cutting edge smart beta solutions to our institutional clients. The significant interest and growth in smart beta strategies is driven by investors looking to improve risk-adjusted returns, manage volatility, and access more sophisticated weighting methodologies. Through our partnership with ERI Scientific Beta, investors will benefit from transparent smart beta index replication using Morgan Stanley’s market leading execution platform.”